Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Predictive and/or Prognostic Biomarkers of (Potential) Clinical Relevance

PD-L1 Staining

The tumoural expression of PD-L1, assessed by immunohistochemistry (IHC) staining, has been identified as a biomarker associated with a higher chance of tumour response in patients treated with anti-PD-L1 antibodies and a better OS in multiple tumour types. The PD-L1 status of a tumour relies both on the IHC staining kit and the scoring methods. Because of the heterogeneity of assays, there is no consensus on a cut-off defining a PD-L1-high tumour. PD-L1 can be expressed either constitutively via an oncogenic pathway or induced by inflammatory cytokines such as interferon-gamma (IFN-λ) (Figure 2). IFN-λ can also lead to the upregulation of PD-L1 at the surface of any cell in the tumour microenvironment, and activated T cells could be double-positive for PD-1 and PD-L1.

Figure 2: Expression of PD-L1 on tumour cells

Figure 2: Expression of PD-L1 on tumour cells.

(a) In some tumours, constitutive oncogenic signalling can upregulate PD-L1 expression on all tumour cells, independently of inflammatory signals in the tumour microenvironment. Activation of the Akt and signal transducer and activator of transcription 3 (STAT3) pathways has been reported to drive PD-L1 expression.

(b) In some tumours, PD-L1 is induced in response to inflammatory signals. Adaptive induction may be a common mechanism for the expression of multiple immune checkpoint molecules in tumours.

Abbreviations: IFN, interferon; MHC, major histocompatibility complex; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; STAT, signal transducer and activator of transcription; TCR, T cell receptor.

Pardoll DM. Figure 4: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252–264. Reprinted with permission of Nature/Springer/Palgrave. Copyright ©2012.

Pembrolizumab is, at present, the only anti-PD-1 antibody to be approved by the Food and Drug Administration (FDA) for a selected population of PD-L1-positive patients in non-small cell lung cancer (NSCLC) and gastric cancer.

Inflammatory Tumours and CD8+ T cells

In several tumour types, tumours with IFN-λ gene expression profile and a high level of tumour-infiltrative CD8+ T cells have better responses and survival following anti-PD-(L)1 therapy.

Mutational Load

Tumours with a high mutational load have been correlated with OS benefits following treatment with ipilimumab in MM, with pembrolizumab in NSCLC and with atezolizumab in bladder cancers. It is currently believed that a high tumour mutation burden (TMB) yields numerous immunogenic cancer cell neo-epitopes, that may be recognised by T cells upon presentation by MHC molecules. However, the TMB seems to be a prognostic marker independent of the intratumoural inflammatory gene expression profile. The assessment of TMB is currently evaluated from either tumour samples or circulating tumour DNA.

Mismatch Repair Status

Tumours with DNA mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) have shown great sensitivity to anti-PD-(L)1 therapies. It is currently believed that tumours harbouring an erroneous MMR system will accumulate DNA mutations, which can lead to the presence of high levels of mutation-associated neoantigens, most recognised by immune cells. Tumours identified as having a dMMR/MSI-H status are eligible for treatment with pembrolizumab in the USA.

Blood Biomarkers

A high neutrophil to lymphocyte ratio has been associated with poor outcomes in patients treated with ipilimumab and anti-PD-(L)1 therapy across different tumour types. High levels of serum lactate dehydrogenase (LDH) or soluble CD25 have been associated with poor prognosis, although none is currently used in the clinic.


In preclinical models, the gut microbiota has been identified as a key modulator of the immune system by enhancing T cell activation and infiltration into tumours. The impact of the gut microbiome on anti-PD-(L)1 efficacy remains to be demonstrated in humans, but is currently under active investigation.

Technical Procedures Clinical Results

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.